FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 2002

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PENHOET EDWARD					2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]									ck all applica Director	able)	g Perso		ner	
(Last) (First) (Middle) ONE EMBARCADERO CENTER SUITE 3700				04	3. Date of Earliest Transaction (Month/Day/Year) 04/05/2010									below)	give title		Other (s below)		
(Street) SAN FRANCISCO CA 94111					_ 4.	If Ame	ename	ent, Date of	Originai	Filea	(Month/Day	Line)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	itate)	(Zip)																
			ble I - No						1	Dis	_						I		
			Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			Beneficia Owned Fo	s lly ollowing	Form (D) or	: Direct I r Indirect I str. 4)	7. Nature of ndirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	or	Price	Transacti	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)
Common Stocks			04/0	04/05/2010				М		26,250	,	A	\$2.23	26,250		D			
Common Stocks			04/0	05/2010				M		15,000		A	\$0.96	41,250			D		
Common Stocks			04/0	05/20	5/2010					0	A	(1)	\$0.00	5,484,063				By Fund ⁽¹⁾	
Common Stocks 04/05				05/20	/2010		M		0	A	(2)	\$0.00	180,204				By Fund ⁽²⁾		
			Table II -								osed of, convertib				Owned		•		•
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Date,		ansaction de (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerci on Da Day/Y		e of Securit		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	or Nu of		Number		Transaction(s) (Instr. 4)			
Common Stock Option	\$2.23	04/05/2010			M			26,250 ⁽³⁾	(4)		06/10/2018	Comm		26,250	\$0.00	0		D	
Common Stock	\$0.96	04/05/2010			M		15,000 ⁽³⁾		(5)		06/11/2019	Comm		15,000	\$0.00	0		D	

Explanation of Responses:

- 1. These securities are held of record by Alta BioPharma Partners II, L.P. ("ABPII"). Alta BioPharma Management II, LLC ("ABMII") is the General Partner of ABPII. Edward Penhoet is a director of ABMII and exercise shared voting and investment power with respect to the shares owned by ABPII. He disclaims beneficial ownership of such securities, except to the extend of his or her proportionate pecuniary interest
- 2. These securities are held of record by Alta Embarcadero BioPharma Partners II, LLC ("AEBPII"). Alta Partners II, Inc. ("APII") provides investment advisory services to ABPII and AEBPII. The reporting person disclaims beneficial ownership of all such shares except to the extend of his or her proportionate pecuniary interest therein.
- 3. Edward Penhoet resigned from the Board of Directors on January 5, 2010. In accordance with the terms of Mr. Penhoet's Stock Options, all unvested shares underlying such options immediately expired on January 5, 2010, and on April 5, 2010, he exercised the vested portion of his Common Stock Options.
- 4. Per the terms of the option, 25% of the stock shares vested on June 10, 2009 and the remaining shares were scheduled to vest monthly thereafter at a rate of 2.0834% per month until fully vested on June 10, 2012 (the fourth anniversary of the date of election to the board). As described in footnote 3, the option ceased vesting on January 5, 2010.
- 5. Per the term of the option, the stock option was scheduled to vest at a rate of 8.3334% of option share beginning on June 11, 2009, with final vesting of all remaining shares on or before the date of the Company's 2010 Annual Meeting of Stockholders. As described in footnote 3, the option ceased vesting on January 5, 2010.

Remarks:

/s/ Edward Penhoet

04/05/2010

** Signature of Reporting Person

Date

 $Reminder: \ Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.